Zhang Chunbo - Guangzhou Baiyunshan Deputy Director
| GZPHFDelisted Stock | USD 2.88 0.00 0.00% |
Insider
Zhang Chunbo is Deputy Director of Guangzhou Baiyunshan Pharmaceutical
| Age | 46 |
| Phone | 86 20 6628 1218 |
| Web | https://www.gybys.com.cn |
Guangzhou Baiyunshan Management Efficiency
The company has return on total asset (ROA) of 0.0356 % which means that it generated a profit of $0.0356 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1281 %, meaning that it generated $0.1281 on every $100 dollars invested by stockholders. Guangzhou Baiyunshan's management efficiency ratios could be used to measure how well Guangzhou Baiyunshan manages its routine affairs as well as how well it operates its assets and liabilities.Guangzhou Baiyunshan Pharmaceutical has accumulated 752.81 M in total debt with debt to equity ratio (D/E) of 0.33, which is about average as compared to similar companies. Guangzhou Baiyunshan has a current ratio of 1.62, which is within standard range for the sector. Debt can assist Guangzhou Baiyunshan until it has trouble settling it off, either with new capital or with free cash flow. So, Guangzhou Baiyunshan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guangzhou Baiyunshan sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guangzhou to invest in growth at high rates of return. When we think about Guangzhou Baiyunshan's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Yongfeng Zhang | Amphastar P | 77 | |
| James DVM | Durect | 67 | |
| Carlos Cortez | Cronos Group | 51 | |
| Ziping Luo | Amphastar P | 74 | |
| MSc MPhil | Redhill Biopharma | 49 | |
| Shayne Laidlaw | Cronos Group | N/A | |
| Andrea Sabens | Lantheus Holdings | 45 | |
| Peter Langosh | Amphastar P | 71 | |
| Micha BenChorin | Redhill Biopharma | 55 | |
| Z Mahdavi | Catalent | N/A | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| Karen Santiago | Catalent | 53 | |
| Jacob MBA | Amphastar P | 50 | |
| Robert Polzer | Zoetis Inc | 55 | |
| Norman MD | Durect | 71 | |
| Ricci Whitlow | Catalent | 51 | |
| J McFarland | Zoetis Inc | 61 | |
| Mark Kinarney | Lantheus Holdings | N/A | |
| Robert Kelly | Zoetis Inc | 48 | |
| CFA Marshall | Lantheus Holdings | 57 | |
| James Holm | Cronos Group | 41 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0356 |
Guangzhou Baiyunshan Leadership Team
Elected by the shareholders, the Guangzhou Baiyunshan's board of directors comprises two types of representatives: Guangzhou Baiyunshan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Guangzhou. The board's role is to monitor Guangzhou Baiyunshan's management team and ensure that shareholders' interests are well served. Guangzhou Baiyunshan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Guangzhou Baiyunshan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Changhai Wu, Vice General Manager, Executive Director and Member of Nomination and Remuneration Committee | ||
| Xuezhen Huang, Secretary of the Board | ||
| Zhang Chunbo, Deputy Director | ||
| Juyan Liu, Ex Director | ||
| Chuyuan Li, Chairman and Chairman of Strategic Devel. and Investment Committee | ||
| Hong Li, General Manager | ||
| Haoshan Zheng, Deputy General Manager | ||
| Jianxiong Zheng, Deputy Mang | ||
| Ning Cheng, Executive Director and Member of Budget Committee | ||
| Jun Yang, Vice Chairman |
Guangzhou Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Guangzhou Baiyunshan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0356 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 5.65 B | |||
| Shares Outstanding | 219.9 M | |||
| Shares Owned By Institutions | 33.99 % | |||
| Price To Earning | 6.77 X | |||
| Price To Book | 0.78 X | |||
| Price To Sales | 0.11 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Guangzhou Pink Sheet
If you are still planning to invest in Guangzhou Baiyunshan check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Guangzhou Baiyunshan's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Transaction History View history of all your transactions and understand their impact on performance |